Insulin-free Cow Milk Formula in Prevention of Type 1 Diabetes Associated Autoimmunity - FINDIA Pilot Study
This study has been completed.
Sponsor:
National Institute for Health and Welfare, Finland
Collaborators:
Valio Ltd
University of Turku
Helsinki University
University of Eastern Finland
Information provided by:
National Institute for Health and Welfare, Finland
ClinicalTrials.gov Identifier:
NCT01055080
First received: January 22, 2010
Last updated: NA
Last verified: January 2010
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether weaning to whey-based hydrolysed formula or essentially bovine insulin free whey-based FINDIA formula instead of standard cow's milk based formula is effective in the prevention of type 1 diabetes associated beta-cell autoimmunity in children at genetic risk of type 1 diabetes.
| Condition | Intervention |
|---|---|
|
Beta-cell Autoimmunity |
Dietary Supplement: Cow's milk formula |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Pilot Study of Dietary Prevention of Type 1 Diabetes Associated Beta-cell Autoimmunity in Children at Genetic Risk |
Resource links provided by NLM:
Genetics Home Reference related topics:
type 1 diabetes
Drug Information available for:
Insulin human
U.S. FDA Resources
Further study details as provided by National Institute for Health and Welfare, Finland:
Primary Outcome Measures:
- Beta-cell autoantibodies [ Time Frame: 3,6,12,24,36,48,60,72 months ] [ Designated as safety issue: No ]
| Enrollment: | 987 |
| Study Start Date: | May 2002 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | June 2006 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Placebo Comparator: Cow's milk formula |
Dietary Supplement: Cow's milk formula
Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
|
| Active Comparator: Bovine insulin-free whey based formula |
Dietary Supplement: Cow's milk formula
Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
|
| Active Comparator: Whey-based hydrolysed formula |
Dietary Supplement: Cow's milk formula
Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
|
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- HLA-conferred genetic susceptibility for type 1 diabetes
Exclusion Criteria:
- Pre-term, maternal diabetes with insulin treatment
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01055080
Sponsors and Collaborators
National Institute for Health and Welfare, Finland
Valio Ltd
University of Turku
Helsinki University
University of Eastern Finland
Investigators
| Principal Investigator: | Outi Vaarala, MD PhD | National Institute for Health and Welfare, Finland |
More Information
No publications provided by National Institute for Health and Welfare, Finland
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Outi Vaarala, National Institute for Health and Welfare, Finland |
| ClinicalTrials.gov Identifier: | NCT01055080 History of Changes |
| Other Study ID Numbers: | FINDIA2002 |
| Study First Received: | January 22, 2010 |
| Last Updated: | January 22, 2010 |
| Health Authority: | Finland: Ethics Committee |
Keywords provided by National Institute for Health and Welfare, Finland:
|
type 1 diabetes beta-cell autoantibodies cow's milk formula bovine insulin |
Additional relevant MeSH terms:
|
Diabetes Mellitus, Type 1 Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases |
Immune System Diseases Insulin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013